IDEX Biometrics - Approved Prospectus - 13 Nov 2024

GlobeNewswire11-14

Reference is made to the stock exchange announcement issued by IDEX Biometrics ASA (the “Company”) on 17 September 2024 regarding the successful private placement of 466,666,666 new shares (“Private ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483830117?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QQeKtwoKhTL6_JGsJV0s1w--~B/aD0yMzc7dz03MTk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/887aecc0000c1a8ae7a01eafc452a865","is_english":true,"pubTime":"2024-11-14 01:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483830117","market":"us","top_or_hot":-1,"title":"IDEX Biometrics - Approved Prospectus - 13 Nov 2024","media":"GlobeNewswire","content":"<div>\n<p>Reference is made to the stock exchange announcement issued by IDEX Biometrics ASA (the “Company”) on 17 September 2024 regarding the successful private placement of 466,666,666 new shares (“Private ...</p>\n\n<a href=\"https://finance.yahoo.com/news/idex-biometrics-approved-prospectus-13-170000875.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEX Biometrics - Approved Prospectus - 13 Nov 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEX Biometrics - Approved Prospectus - 13 Nov 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 01:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/idex-biometrics-approved-prospectus-13-170000875.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reference is made to the stock exchange announcement issued by IDEX Biometrics ASA (the “Company”) on 17 September 2024 regarding the successful private placement of 466,666,666 new shares (“Private ...</p>\n\n<a href=\"https://finance.yahoo.com/news/idex-biometrics-approved-prospectus-13-170000875.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDXAD","symbol_name":"IDEX Biometrics ASA","start_time":0,"source_url":"https://finance.yahoo.com/news/idex-biometrics-approved-prospectus-13-170000875.html","article_id":"2483830117","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QQeKtwoKhTL6_JGsJV0s1w--~B/aD0yMzc7dz03MTk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/887aecc0000c1a8ae7a01eafc452a865"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483830117","pubTimestamp":1731517200,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Reference is made to the stock exchange announcement issued by IDEX Biometrics ASA  on 17 September 2024 regarding the successful private placement of 466,666,666 new shares , and the possible subsequent offering of up to 140,000,000 new shares .As stated in the announcement on 17 September 2024, the listing of the Private Placement Shares and the offering and listing of the Subsequent Offering Shares remained subject to approval of a prospectus  by the Financial Supervisory Authority of Norway , and the subsequent publication of such Prospectus by the Company. Further, the admission to trading of warrants issued to participants in the Private Placement and the Subsequent Offering, as well as the listing of certain shares issued in the private placement resolved on 20 August 2024, remained subject to the approval and publication of the Prospectus.About this notice: This notice was issued by Erling Svela, Vice President of Finance, on 13 November 2024 at 18:00 CET on behalf of IDEX Biom","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDXAD":"IDEX Biometrics ASA","BK4149":"建筑机械与重型卡车","BK4148":"电子元件","IDEX":"优点互动"},"translate_title":"IDEX Biometrics–批准的招股说明书–2024年11月13日","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDEX":1,"IDXAD":0.9},"content_text":"Reference is made to the stock exchange announcement issued by IDEX Biometrics ASA (the “Company”) on 17 September 2024 regarding the successful private placement of 466,666,666 new shares (“Private Placement” and the “Private Placement Shares”), and the possible subsequent offering of up to 140,000,000 new shares (“Subsequent Offering” and the “Subsequent Offering Shares”).\nAs stated in the announcement on 17 September 2024, the listing of the Private Placement Shares and the offering and listing of the Subsequent Offering Shares remained subject to approval of a prospectus (\"Prospectus\") by the Financial Supervisory Authority of Norway (“FSA”), and the subsequent publication of such Prospectus by the Company. Further, the admission to trading of warrants issued to participants in the Private Placement and the Subsequent Offering, as well as the listing of certain shares issued in the private placement resolved on 20 August 2024, remained subject to the approval and publication of the Prospectus.\nThe FSA has today approved the Prospectus.\nAs a result of the above, the subscription period for the Subsequent Offering starts on 15 November 2024 and expires on 29 November 2024 at 16:30 CET. For further information on the Subsequent Offering, please refer to the Prospectus.\nThe Prospectus is enclosed with this notice. It will also be available in electronic format at https://www.idexbiometrics.com/investors/share- information/prospectuses/. Printed copies of the Prospectus may be obtained free of charge at the office of IDEX Biometrics ASA, Dronning Eufemias gate 16, NO- 0191 Oslo, Norway, telephone +47 6783 9119 or by e-mail: companysecretary@idexbiometrics.com.\nArctic Securities AS acted as financial advisor and bookrunner in connection with the Private Placement and the Subsequent Offering (the \"Manager\"). Ræder Bing advokatfirma AS acted as the Company's legal advisor. Advokatfirmaet Thommessen AS acted as legal advisor to the Manager.\nContact persons: Marianne Bøe, Head of Investor Relations Kristian Flaten, CFO E-mail: ir@idexbiometrics.com Tel: +47 6783 9119\nAbout IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.\nFor more information, visit www.idexbiometrics.com (http://www.idexbiometrics.com)\nAbout this notice: This notice was issued by Erling Svela, Vice President of Finance, on 13 November 2024 at 18:00 CET on behalf of IDEX Biometrics ASA. The information shall be disclosed according to section 5-8 of the Norwegian Securities Trading Act (STA) and released in accordance with section 5-12 of the STA.\n Attachment \n\n 2024-11-13 Prospectus w subscr form - Pub","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483830117"}